Lupin Pharmaceuticals Inc. recalls Levothyroxine Sodium Tablets, Lupin, 75 mcg (0.075mg), 1000 Tablets
Baltimore, Maryland 21202 … beginning December 20, 2024, in a drug recall whose distribution included Ohio.
Lupin Pharmaceuticals Inc. began a drug recall on December 20, 2024 whose reported distribution included Ohio. FDA
What the record shows
recalled Levothyroxine Sodium Tablets, Lupin, 75 mcg (0.075mg), 1000 Tablets, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. The stated reason: Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study. FDA graded it Class II — use may cause temporary or medically reversible health consequences. Quantity affected: 480 1000-count bottles. The recall is listed as terminated. FDA
Context
By the numbers
- Date of record: December 20, 2024 FDA
- Recall number: D-0167-2025 FDA
- Recalls in this action: 1 FDA
- Recalling firm: Lupin Pharmaceuticals Inc. FDA
- Product: Levothyroxine Sodium Tablets, Lupin, 75 mcg (0.075mg), 1000 Tablets, Rx Only, Manufactured for: Lupin Pharmaceuticals… FDA
- Reason for recall: Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity… FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | D-0167-2025 |
|---|---|
| Recalls in this action | 1 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Product | Levothyroxine Sodium Tablets, Lupin, 75 mcg (0.075mg), 1000 Tablets, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited, Pithampur (M.P)- 454 775 INDIA, NDC# 68180-967-03 |
| Reason for recall | Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study. |
| Classification | Class II — use may cause temporary or medically reversible health consequences |
| Recall type | drug |
| Quantity | 480 1000-count bottles |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20241220 |
| Reported | 20250108 |
| Distribution | One US distributor in Ohio. |
| Firm location | Baltimore, MD, United States |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.